Imugene MD Shares With JustStocks Video Plans For Phase 1 onCARlytics Combination Study

Imugene Limited (ASX: IMU) Managing Director Leslie Chong shares an exciting update with JustStocks Video regarding the company’s Phase 1 clinical trial of their CD19 oncolytic virotherapy drug candidate, onCARlytics. The trial has successfully cleared its first cohort within the monotherapy arm and is now poised to commence combination dosing on solid tumor patients with the CD19-targeting drug, blinatumomab (marketed as Blincyto® by Amgen).

Chong explains that this groundbreaking clinical trial targets adult patients with advanced or metastatic solid tumors, with the primary goal of evaluating the safety and efficacy of two administration routes: intratumoural (IT) injection and intravenous (IV) infusion. These routes will be tested either alone or in combination with blinatumomab.

OnCARlytics is a pioneering CD19-expressing oncolytic virus designed to infiltrate tumor cells and induce the expression of the CD19 protein on their surface. This process creates a specific target for CD19-targeting therapies, offering promising potential in the treatment of various cancers.


Articles of Interest